+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety of two different doses of a Chlamydia mRNA vaccine candidate in adults. The study includes participants aged 18 to 29 years who do not have prior exposure to Chlamydia trachomatis, and those aged 18 to 44 years who are seropositive. The study aims to assess safety and possibly detect early immune responses to the vaccine. Participants are divided into two groups receiving either the first or second dose of the vaccine, or a placebo, given as three intramuscular injections. There are separate cohorts based on Chlamydia trachomatis serostatus. The study lasts about 18 months for each participant, including a 12-month follow-up after the last injection. During the study, participants will be monitored for immediate reactions after injections, injection site and systemic symptoms in the days following, and any adverse events for up to a year after vaccination. Laboratory tests will also be performed to check for abnormal results. Researchers will assess all serious adverse events throughout the study to evaluate safety comprehensively.

Age: 18Years - 44YearsAll GendersPhase 1
7 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, how the body processes, and the effects of a new drug called TRB-061, given as injections under the skin, in healthy adults and people with moderate-to-severe atopic dermatitis AD. This Phase 1a1b study includes healthy volunteers and patients to explore different dosing schedules and amounts in a randomized, double-blind, placebo-controlled setting. The study has three parts Part 1 involves healthy adults receiving a single dose of TRB-061 or placebo Part 2 includes healthy adults receiving three doses every 4 weeks over 8 weeks and Part 3 involves participants with moderate-to-severe AD receiving four doses every 4 weeks over 12 weeks. In Part 3, participants may also opt to switch treatments after the first period. Placebo doses match the appearance and schedule of TRB-061. Participants will attend multiple visits for dosing and follow-up, including safety checks, blood tests to measure drug levels, and assessments of side effects up to 12 weeks after dosing in Part 1, 10 weeks after dosing in Part 2, and through the end of the study in Part 3. Researchers will track adverse events, drug levels in the blood, and responses to treatment during the study, which runs until early 2028.

Age: 18Years - 70YearsAll GendersPhase 1
19 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 2b study to evaluate the safety, immune response, and effectiveness of a new bivalent protein vaccine against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV in adults aged 60 years and older. This randomized, placebo-controlled, observer-blind trial aims to prevent lower respiratory tract diseases caused by these viruses in an elderly population. The study is sponsored by Sanofi and focuses on vaccine prevention in healthy volunteers. Participants will receive a single intramuscular injection of either the bivalent RSVHMPV protein vaccine or a matching placebo. The study includes an initial Safety Lead-in Cohort of 200 participants randomized 11 to vaccine or placebo, followed by a Main Cohort of 7,800 participants also randomized 11 after safety review. Both groups receive only one dose and are monitored over time to assess vaccine effects and safety. Throughout the study, participants will be monitored for respiratory infections caused by RSV and HMPV from 14 days up to 12 months after vaccination. Researchers will also evaluate immune responses by measuring antibody levels before vaccination and at multiple time points afterward. Safety assessments include tracking adverse events immediately after vaccination and for up to one year. The total participation duration spans about 12 months, covering vaccination, follow-up visits, and safety monitoring.

Age: 60Years +All GendersPhase 2
21 locations